Related Experiment Video
Updated: Dec 16, 2025

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
Anti-N-methyl-D-aspartate-receptor antibody encephalitis combined with syphilis: A case report
Xi-Yu Li1, Zhi-Hong Shi2, Ya-Lin Guan3
1Graduate School, Tianjin Medical College, Tianjin 300070, China.
Background:
Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis is a common type of autoimmune encephalitis characterized by complex clinical signs and variable imaging manifestations. The pathogenesis of the disease is unclear. Syphilis is an infectious disease caused by Treponema pallidum that can invade the nervous and immune systems and cause systemic symptoms. There are few reports of anti-NMDAR encephalitis with syphilis, and the association between them is unknown; both diseases are related to immune system damage. We report a case of anti-NMDAR encephalitis with syphilis.
Case Summary:
A 32-year-old man was admitted to our hospital with complaints of cognitive decline, diplopia, and walking instability during the previous 6 mo. He developed dysarthria, difficulty swallowing, and involuntary shaking of his head, neck, and limbs during the month prior to presentation. Cranial magnetic resonance imaging showed symmetrical abnormal signals in the pons, midbrain, and bilateral basal ganglia, and inflammatory demyelination was considered. The diagnosis of syphilis was confirmed based on the syphilis diagnosis test and the syphilis rapid test. He was given anti-syphilis treatment, but the above symptoms gradually worsened. Anti-NMDAR antibody was positive in cerebrospinal fluid but was negative in serum. Due to the cerebrospinal fluid findings, anti-NMDAR encephalitis was a consideration. According to the patient's weight, he was treated with intravenous methylprednisolone 1 g QD for 5 d, with the dose gradually decreased for 6 mo, and immunoglobulin 25 g QD for 5 d; his symptoms improved after treatment.
Conclusion:
This case shows that anti-NMDAR encephalitis may be combined with syphilis, which should be recognized to avoid misdiagnosis and treatment delay.
Insights
Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis can co-occur with syphilis. Recognizing this association is crucial for accurate diagnosis and timely treatment of autoimmune encephalitis and infectious diseases.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis is an autoimmune disorder with complex neurological symptoms.
- Syphilis, caused by Treponema pallidum, affects the nervous and immune systems, with its association with NMDAR encephalitis being rarely reported.
Observation:
- A 32-year-old male presented with progressive cognitive decline, diplopia, and ataxia, followed by dysarthria and involuntary movements.
- Cranial MRI revealed symmetrical abnormal signals in the brainstem and basal ganglia, suggestive of inflammatory demyelination. Syphilis was confirmed, but symptoms worsened despite treatment.
- Anti-NMDAR antibodies were detected in cerebrospinal fluid, leading to a diagnosis of anti-NMDAR encephalitis.
Findings:
- The patient received treatment for anti-NMDAR encephalitis with intravenous methylprednisolone and immunoglobulin.
- Symptomatic improvement was observed following immunotherapy, suggesting a link between the two conditions.
Implications:
- This case highlights the importance of considering concurrent syphilis in patients diagnosed with anti-NMDAR encephalitis.
- Early recognition and appropriate management of both conditions are essential to prevent misdiagnosis and treatment delays in complex neurological presentations.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022